Physician profile
Jerome Kramer
NPI 1437259637
$3,173.31
in general payments reported to CMS, 2019-2025
20 companies · $744 in 2025
The $744 reported for 2025 was more than what 81% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $295 · 2021: $129 · 2022: $133 · 2023: $666 · 2024: $1,031 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $576.10 | 2020-2025 | Precision 1, Hydrus Microstent, Total30 |
| Sun Pharmaceutical Industries INC. | $471.28 | 2020-2025 | Cequa |
| Bausch & Lomb Americas INC. | $386.48 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $247.18 | 2024-2025 | Oxervate |
| Amgen INC. | $205.80 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $194.84 | 2023-2024 | |
| Coopervision INC. | $165.98 | 2021-2023 | Myday Contact Lens |
| Sight Sciences, INC. | $140.00 | 2023 | Tearcare System |
| Tarsus Pharmaceuticals, INC. | $118.59 | 2024 | Xdemvy |
| Rxsight INC | $93.75 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Visioneering Technologies, INC. | $92.55 | 2019 | |
| Harrow Eye, LLC | $81.58 | 2025 | Vevye |
| Abbvie INC. | $77.18 | 2022 | |
| Horizon Therapeutics Plc | $77.17 | 2023 | Tepezza |
| Asd Specialty Healthcare, LLC | $62.15 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $58.26 | 2019 | |
| Genzyme Corporation | $55.85 | 2020 | |
| Novartis Pharmaceuticals Corporation | $32.30 | 2021-2022 | |
| Shire North American Group INC | $24.13 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.